Vericiguat in patients with acute coronary syndrome and reduced ejection fraction: the EVE-ACSrEF study [PDF]
BMC Cardiovascular DisordersBackground Preclinical research has demonstrated that vericiguat can improve myocardial microcirculation. However, real-world evidence of using vericiguat alongside guideline-directed medical therapy (GDMT) in patients with acute coronary syndrome (ACS ...
Xinying Shi +8 more
doaj +2 more sources
Precision MedicationBackground: Heart failure (HF) bears a heavy disease burden, and vericiguat is the only guanylate cyclase stimulator proved to improve its prognosis. However, its clinical use needs a further improvement.
Tingting Li +4 more
doaj +2 more sources
Vericiguat improves cardiac remodelling and function in rats with doxorubicin‐induced cardiomyopathy
ESC Heart FailurePurpose Vericiguat, a soluble guanylate cyclase (sGC) stimulator, has been demonstrated effective in improving prognosis of patients with heart failure with reduced ejection fraction. However, there are limited data concerning the effect of vericiguat in
Wen Chen +6 more
doaj +2 more sources
Biomedicines, 2021 Vascular cognitive impairment (VCI) is characterized by impairments in cerebral blood flow (CBF), endothelial function and blood–brain barrier (BBB) integrity.
Ellis Nelissen +9 more
doaj +2 more sources
Randomized controlled trial of vericiguat in patients with coronary microvascular dysfunction causing stable chest pain (V-COM): study protocol for a randomized control trial [PDF]
Journal of Cardiovascular Magnetic Resonance: Background: Previous studies have shown that ∼50% of patients with stable chest pain have no obstructive coronary artery disease (CAD), yet remain at higher risk of major adverse cardiovascular events (MACE) compared to patients without chest pain ...
Cho-Kiu Lo +22 more
doaj +2 more sources
Association Between Vericiguat and Clinical Outcomes Across Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [PDF]
Reviews in Cardiovascular MedicineBackground: Heart failure (HF) remains a major global health burden, with mortality continuing to rise despite therapeutic advances.
Yusra Minahil Nasir +9 more
doaj +2 more sources
From VICTORIA to VICTOR: Where Vericiguat Fits in HFrEF Care [PDF]
Journal of Education, Health and SportBackground. Vericiguat, an oral soluble guanylate cyclase stimulator, augments impaired NO-sGC-cGMP signaling in heart failure with reduced ejection fraction (HFrEF).
Katarzyna Skibicka +3 more
doaj +2 more sources
Initiation, titration, and safety of vericiguat for treatment of heart failure in United States clinical practice [PDF]
American Heart Journal PlusStudy objective: To evaluate the following among new users of vericiguat: up-titration patterns, factors associated with up-titration, occurrence of hypotension/syncope, predictors of hypotension/syncope. Design: Retrospective cohort study (linked claims
Stephen J. Greene +5 more
doaj +2 more sources
Vericiguat – possibly next weapon to overcome heart failure. Review of latest literature [PDF]
Journal of Education, Health and SportIntroduction Heart failure (HF) is a common clinical syndrome characterized by symptoms such as breathlessness and fatigue, affecting 1-2% of adults in developed countries.
Mikolaj Biskupski +9 more
doaj +2 more sources
Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studies [PDF]
Frontiers in Cardiovascular MedicineHeart failure is associated with a high risk of morbidity, mortality, and healthcare resource use. Its pathophysiology and treatment are complex and involve various neurohormonal systems.
Carlos Escobar +8 more
doaj +2 more sources